Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive
  • Overview
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Sustainability
• Press

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2003

Search

Here you find Investor News of year 2003. Ad-hoc messages issued in year 2003 can be found here.

Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR news via E-Mail, RSS Feed or SMS.

Tuesday December 30, 2003

Bayer: All subgroups and service companies now separate legal entities

Bayer MaterialScience AG, Bayer Business Services GmbH and Bayer Industry Services GmbH & Co. OHG entered in the commercial register

Thursday December 18, 2003

FDA grants Cipro® additional six months marketing exclusivity

Monday December 15, 2003

Bayer to take impairment charges of about EUR 2.2 billion

Cash flows and dividend potential not affected

Thursday December 11, 2003

Bayer HealthCare AG:

Pharmaceutical Division Concentrates Research in Biotech and Urology

Tuesday December 09, 2003

Bayer HealthCare AG:

Factor Xa-Inhibitor: Promising results in three phase I studies

First data presented at the 45th Annual Meeting of the American Society of Hematology

Tuesday December 09, 2003

FDA Advisory Committee underscores need for greater understanding of Aspirin's benefit in appropriate patient populations

Bayer committed to ongoing work with FDA to advance public health goal of broader Aspirin use in appropriate patients to reduce burden of heart disease

Thursday November 20, 2003

Bayer and Onyx Announce New Data on Dual Mechanism of Action of BAY 43-9006

Updated Phase II Data Evaluating Novel Signal Transduction Inhibitor in Kidney Cancer Also Released

Tuesday November 11, 2003

Bayer AG Fall Financial News Conference

Werner Wenning: Third-quarter results in line with expectations

Sales increase 4.6 percent after adjustment for portfolio and exchange rate effects / EBIT up 53 percent before special effects / Net debt cut to EUR 6.9 billion

Friday November 07, 2003

Werner Wenning continues systematic realignment:

Bayer plans stock market flotation for chemicals activities and strategic refocus of health care business

Supervisory Board approves Management Board plans / Focus on core businesses should enhance Bayer’s competitiveness / New company to be positioned among Europe’s leading chemical enterprises / Pharmaceuticals business to be retained as stand-alone solution

Wednesday October 29, 2003

Bayer divests its interest in Millennium

CSFB acquired shares for resale

Monday October 27, 2003

Bayer HealthCare AG:

Bayer and Millennium´s successful research collaboration concludes

Industrialized genomic approach drives discovery of more than 460 targets; Bayer receives extended access to proprietary targets

Monday October 27, 2003

Bayer and Onyx

Bayer and Onyx Initiate Pivotal Phase III Clinical Trial in Kidney Cancer

Phase II Interim Data from Single-Agent Study in Kidney Cancer also Reported

Tuesday October 14, 2003

Bayer CropScience and Monsanto Reach Agreement Providing Farmers Broader Access to Patented Technology

Agreement Settles Multiple Patent Disputes

Thursday October 09, 2003

Bayer HealthCare and GSK:New LEVITRA™ (vardenafil HCl) PROVEN Study Showed Once More Success with Levitra

Men with ED Taking Levitra Reported Significant Improvement in Erectile Function

Thursday October 02, 2003

Bayer Pursues Divestiture of Plasma Business

Kogenate® Business Not Included as Part of Initiative

Tuesday September 30, 2003

Bayer HealthCare, Bayer Chemicals and Bayer Technology Services now legally independent too

Bayer CEO Wenning: New corporate structure is the basis for future success

Wednesday September 17, 2003

U.S. District Court Finds in Favor of Bayer

Class action certification denied in Baycol litigation

Friday August 29, 2003

FDA approves Once-Daily Cipro® XR for the treatment of complicated urinary tract infections

Thursday August 28, 2003

Bayer Biological Products Receives FDA Approval for Gamunex®

Breakthrough Production Process and Unprecedented Clinical Trials Support First new Immunoglobulin Intravenous (IGIV) Product in a Decade

Wednesday August 20, 2003

USA:

FDA Grants Bayer Approval for Levitra®

Friday August 15, 2003

Bayer agrees to sell Walothen GmbH

Further portfolio streamlining

Wednesday August 06, 2003

Business performance in second quarter of 2003

Bayer boosts operating result (EBIT) by 80 percent

- First-half EBIT up 40 percent to EUR 1.5 billion - CEO Wenning: “We are quite satisfied with our performance in the first half” - Company confirms forecast of double-digit earnings growth for the full year

Friday June 13, 2003

Bayer: Moody's downgrade incomprehensible

Debt reduction target exceeded, operating profit expected to grow

Wednesday May 07, 2003

Bayer reports on the first quarter of 2003:

Operating result up 31 percent

- Operating profit climbs 80 percent before one-time items - Net income rises 12 percent to EUR 586 million - Further substantial reduction in net debt

Friday April 25, 2003

Bayer: First-quarter sales improve by more than 4 percent - Operating result also up year on year

Double-digit growth in operating result predicted for 2003 / Lipobay/Baycol: more settlement agreements concluded in U.S.

Wednesday March 26, 2003

Excellent addition to the cardiovascular portfolio

Bayer launches Kinzalmono® and Kinzalkomb®

Innovative drug products for the treatment of high blood pressure

Monday March 24, 2003

Bayer CropScience: Completion of product sale to BASF

Divestments subsequent to acquisition of Aventis CropScience

Tuesday March 18, 2003

Bayer Pleased With Verdict in Corpus Christi, Texas Baycol Case

Thursday March 13, 2003

LEADRELEASE: Cautious optimism in light of business development so far this year

Bayer expects growth in operating result in 2003

2002 figures: Net income up 10 percent to 1.1 billion euros / Sales from continuing operations 1 percent lower/ Net debt down significantly to 8.9 billion euros / Ambitious medium-term profit targets declared

Friday March 07, 2003

Bayer and GlaxoSmithKline:

Levitra™ approved for the treatment of erectile dysfunction by European Commission

A new treatment option could mean improved sexual performance for some 30 million men affected by erectile dysfunction in Europe

Thursday March 06, 2003

Bayer proposes EUR 0.90 dividend per share

Supervisory Board backs stance in Lipobay proceedings

Tuesday March 04, 2003

Bayer and Degussa sell PolymerLatex to Soros Private Equity Partners

Tuesday March 04, 2003

Bayer-Shell Isocyanates N.V. joint venture intends to cease operation

Sunday March 02, 2003

Response to ongoing media coverage of Baycol litigation:

Bayer: We will present our case in the courtroom, not in the public

Wednesday February 26, 2003

Baycol lawsuits in the United States:

Bayer defends itself against accusations

Documents taken out of context

Monday February 24, 2003

Bayer Reduces Size of the Group Board of Management

Friday January 31, 2003

Bayer and Aventis end negotiations on biologicals joint venture

Wednesday January 22, 2003

Protection against West Nile virus and Lyme disease

Bayer: New tick product for dogs set to take global veterinary market by storm

Launch to follow regulatory approval in the USA